Samir Patel Rashmikant's Insider Trades & SAST Disclosures
Samir Patel Rashmikant's most recent trade in Akari Therapeutics Plc - ADR was a trade of 225,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 20, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Samir Patel Rashmikant.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 1.12 per share. | 06 Mar 2025 | 406,250 | 3,031,005 (0%) | 0% | 1.1 | 455,000 | American Depositary Shares representing Ordinary Shares |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 406,250 | 406,250 | - | - | Series A Warrants (Right to Buy) | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 406,250 | 406,250 | - | - | Series B Warrants (Right to Buy) | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 152,672,000 | 152,672,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 208,000 | 5,249,511,500 (344%) | 0% | 0.0 | 125 | Ordinary Shares, par value $0.0001 per share |
| Akari Therapeutics Plc - ADR | Rashmikant Patel Samir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Dec 2024 | 3,200,000 | 5,248,903,500 (344%) | 0% | 0.0 | 1,600 | Ordinary Shares, par value $0.0001 per share |
| Akari Therapeutics Plc - ADR | Rashmikant Patel Samir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Dec 2024 | 400,000 | 5,249,303,500 (344%) | 0% | 0.0 | 200 | Ordinary Shares, par value $0.0001 per share |
| Akari Therapeutics Plc - ADR | Samir Patel Rashmikant | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Dec 2024 | 7,500,000 | 5,245,703,500 (343%) | 0% | 0.0 | 3,750 | Ordinary Shares, par value $0.0001 per share |
| Akari Therapeutics Plc - ADR | Samir Patel Rashmikant | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 1,400,000 | 5,238,203,500 (343%) | 0% | 0.0 | 700 | Ordinary Shares, par value $0.0001 per share |
| Akari Therapeutics Plc - ADR | Rashmikant Patel Samir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 1,400,000 | 5,236,803,500 (343%) | 0% | 0.0 | 700 | Ordinary Shares, par value $0.0001 per share |
| Akari Therapeutics Plc - ADR | Patel Samir Rashmikant | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2024 | 419,286,000 | 5,235,403,500 (343%) | 27% | 0.0 | 503,143 | Ordinary Shares, par value $0.0001 per share |
| Akari Therapeutics Plc - ADR | Patel Samir Rashmikant | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2024 | 419,286,000 | 419,286,000 | - | - | Warrants (Right to Buy) | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2024 | 162,604,000 | 162,604,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2024 | 1,404,622,000 | 4,816,117,500 (315%) | 92% | - | Ordinary Shares, par value $0.0001 per share | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2024 | 79,684,000 | 79,684,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 175,080,000 | 175,080,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2024 | 91,396,000 | 91,396,000 (5%) | 5% | 0 | Ordinary Shares, par value $0.0001 per share | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 1,326,258,000 | 1,326,258,000 | - | - | Warrants (Right to Buy) | |
| Akari Therapeutics Plc - ADR | Samir Rashmikant Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 1,326,258,000 | 3,411,495,500 (223%) | 86% | 0.0 | 1,193,632 | Ordinary Shares, par value $0.0001 per share |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges